These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11886161)

  • 1. Prevention in respiratory syncytial virus infections.
    Wolfs TF; Kimpen JL
    Pediatr Pulmonol; 2001; Suppl 23():86-7. PubMed ID: 11886161
    [No Abstract]   [Full Text] [Related]  

  • 2. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
    Manzoni P; Leonessa M; Farina D; Gomirato G
    Pediatr Transplant; 2007 Jun; 11(4):456-7. PubMed ID: 17493231
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prevention of respiratory syncytial virus infections].
    Rossi GA
    Minerva Pediatr; 2002 Apr; 54(2):75-8. PubMed ID: 11981522
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 6. Compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection: results of the second season of the Previeni Study.
    Macagno F;
    Pediatr Med Chir; 2005; 27(3-4):78-87. PubMed ID: 16910455
    [No Abstract]   [Full Text] [Related]  

  • 7. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managed care considerations: vulnerable populations and prevention strategies for respiratory syncytial virus disease.
    Peskin SR
    Manag Care; 2008 Nov; 17(11 Suppl 12):preceding table of contents. PubMed ID: 19097555
    [No Abstract]   [Full Text] [Related]  

  • 10. Main results of a national multicenter study assessing the compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection.
    Macagno F;
    Pediatr Med Chir; 2005; 27(3-4):70-7. PubMed ID: 16910454
    [No Abstract]   [Full Text] [Related]  

  • 11. A health care management company's experience with palivizumab--1 year later.
    Silverman W
    Manag Care; 2003 May; 12(5):49-50. PubMed ID: 12800748
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consideration of palivizumab not justified.
    Clifford RD
    Thorax; 2006 Jun; 61(6):545-6; author reply 546. PubMed ID: 16738045
    [No Abstract]   [Full Text] [Related]  

  • 14. Abbott launches special programme for babies at high risk for respiratory syncytial virus.
    Cardiovasc J S Afr; 2007; 18(1):54. PubMed ID: 17393002
    [No Abstract]   [Full Text] [Related]  

  • 15. RSV disease--is there a role for prevention?
    Lenney W
    Respir Med; 2001 Mar; 95(3):170-2. PubMed ID: 11266232
    [No Abstract]   [Full Text] [Related]  

  • 16. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.
    Hand IL; Noble L; Geiss D; Shotkin A
    Pediatr Infect Dis J; 2008 Feb; 27(2):175-6. PubMed ID: 18174866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
    Korppi M
    Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 19. RSV infection and bronchiolitis: who qualifies for prevention?
    Prescrire Int; 2000 Dec; 9(50):173. PubMed ID: 11475495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RSV: protecting the littlest patients.
    Lauts NM
    RN; 2005 Dec; 68(12):46-51; quiz 52. PubMed ID: 16411554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.